Pergi ke luar talian dengan aplikasi Player FM !
Neal D. Shore, MD, FACS - Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care
Manage episode 395973155 series 1157776
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.
Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Neal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.
Faculty/Planner
Sia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.
Grant/Research Support from Janssen Pharmaceuticals, Inc.
Faculty/Planner
Guru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.
Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.
Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
74 episod
Neal D. Shore, MD, FACS - Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Manage episode 395973155 series 1157776
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.
Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Neal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.
Faculty/Planner
Sia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.
Grant/Research Support from Janssen Pharmaceuticals, Inc.
Faculty/Planner
Guru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.
Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.
Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
74 episod
Все серии
×Selamat datang ke Player FM
Player FM mengimbas laman-laman web bagi podcast berkualiti tinggi untuk anda nikmati sekarang. Ia merupakan aplikasi podcast terbaik dan berfungsi untuk Android, iPhone, dan web. Daftar untuk melaraskan langganan merentasi peranti.